Press release archive | Oxurion — Advancing Science. Enhancing Vision

EN
NL

Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Press release archive

Oxurion NV to Present at the 2019 BIO CEO & Investor Conference
4 Feb 2019
Oxurion NV to Present at 2019 Biotech Showcase Conference and Participate in CEO Power Breakfast Roundtable during the 37th Annual J.P. Morgan Healthcare Conference
19 Dec 2018
Oxurion and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatment of dry AMD
5 Nov 2018
Oxurion supports sight-saving diabetes programs
2 Nov 2018
Oxurion NV Announces the Appointment of Adrienne Graves to its Board of Directors
29 Oct 2018
Oxurion NV to Present at the Upcoming Ophthalmology Innovation Summit and Provide a Clinical Update at the American Academy of Ophthalmology 2018 Annual Meeting
24 Oct 2018
Oxurion NV Extends Partnership with Retina Global in Support of Bolivian Diabetic Retinopathy (BOLDR) Project
22 Oct 2018
Oxurion NV Business Update – Q3 2018
19 Oct 2018
Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for treatment of Idiopathic Macular Telangiectasia Type 1 (MacTel 1)
20 Sep 2018
Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for Treatment of Diabetic Macular Edema (DME)
20 Sep 2018
Oxurion NV to present further scientific findings supporting therapeutic potential of THR-317 and THR-687 as promising new therapies for Diabetic Eye Disease at upcoming EURETINA 2018 in Vienna, Austria
17 Sep 2018
Oxurion NV Announces New Euronext Brussels Stock Ticker “OXUR” and Launch of New Website
10 Sep 2018
ThromboGenics Business Update – H1 2018
6 Sep 2018
ThromboGenics becomes "Oxurion"
3 Sep 2018
Regulated Information - Transparency Statement
27 Jul 2018
ThromboGenics Reports Day 150 Topline Data from its Phase 1/2 Clinical Study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME)
19 Jul 2018
ThromboGenics Plans Name Change to “Oxurion”
27 Jun 2018
ThromboGenics Partners with Prevent Blindness at 2018 Focus on Eye Health National Summit in Washington DC
21 Jun 2018
ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149, a plasma kallikrein inhibitor, for treatment of Diabetic Macular Edema (DME)
25 May 2018
ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018
23 May 2018
ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium
14 May 2018
ThromboGenics Business Update – Q1 2018
9 May 2018
Regulated Information / Transparency Statement
27 Apr 2018
ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combo with anti-VEGF (ranibizumab) for treatment of DME
27 Apr 2018
ThromboGenics announces publication in The Journal of Medicinal Chemistry of preclinical data supporting therapeutic potential of THR-149
6 Apr 2018
ThromboGenics Reports Initial Data from its Clinical Study evaluating THR-317 for the Treatment of Diabetic Macular Edema (DME)
4 Apr 2018
ThromboGenics Business Update – FY 2017
15 Mar 2018
Disclosure in accordance with Belgian Law of 2 May 2007
30 Jan 2018
NOVARTIS PHARMA AG HOLDING 5.69% OF THROMBOGENICS EQUITY CAPITAL
26 Jan 2018